vs

Side-by-side financial comparison of Definitive Healthcare Corp. (DH) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $61.5M, roughly 1.2× Definitive Healthcare Corp.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -1.2%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-1.7M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -1.5%).

Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

DH vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.2× larger
PBYI
$75.5M
$61.5M
DH
Growing faster (revenue YoY)
PBYI
PBYI
+28.9% gap
PBYI
27.7%
-1.2%
DH
More free cash flow
PBYI
PBYI
$16.1M more FCF
PBYI
$14.4M
$-1.7M
DH
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-1.5%
DH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DH
DH
PBYI
PBYI
Revenue
$61.5M
$75.5M
Net Profit
$-9.3M
Gross Margin
76.2%
69.3%
Operating Margin
-43.3%
22.7%
Net Margin
-15.1%
Revenue YoY
-1.2%
27.7%
Net Profit YoY
84.2%
EPS (diluted)
$-0.14
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DH
DH
PBYI
PBYI
Q4 25
$61.5M
$75.5M
Q3 25
$60.0M
$54.5M
Q2 25
$60.8M
$52.4M
Q1 25
$59.2M
$46.0M
Q4 24
$62.3M
$59.1M
Q3 24
$62.7M
$80.5M
Q2 24
$63.7M
$47.1M
Q1 24
$63.5M
$43.8M
Net Profit
DH
DH
PBYI
PBYI
Q4 25
$-9.3M
Q3 25
$-14.8M
$8.8M
Q2 25
$-7.6M
$5.9M
Q1 25
$-107.2M
$3.0M
Q4 24
$-59.1M
Q3 24
$-130.9M
$20.3M
Q2 24
$-213.6M
$-4.5M
Q1 24
$-9.5M
$-4.8M
Gross Margin
DH
DH
PBYI
PBYI
Q4 25
76.2%
69.3%
Q3 25
76.6%
77.7%
Q2 25
76.7%
76.5%
Q1 25
73.9%
77.1%
Q4 24
76.4%
76.4%
Q3 24
78.2%
63.9%
Q2 24
79.2%
77.4%
Q1 24
79.4%
75.5%
Operating Margin
DH
DH
PBYI
PBYI
Q4 25
-43.3%
22.7%
Q3 25
-14.5%
17.6%
Q2 25
-6.9%
12.7%
Q1 25
-312.2%
8.7%
Q4 24
-159.8%
22.6%
Q3 24
-359.5%
27.4%
Q2 24
-579.9%
-4.6%
Q1 24
-25.6%
-5.3%
Net Margin
DH
DH
PBYI
PBYI
Q4 25
-15.1%
Q3 25
-24.7%
16.2%
Q2 25
-12.4%
11.2%
Q1 25
-181.2%
6.5%
Q4 24
-94.8%
Q3 24
-208.8%
25.2%
Q2 24
-335.2%
-9.6%
Q1 24
-15.0%
-11.0%
EPS (diluted)
DH
DH
PBYI
PBYI
Q4 25
$-0.14
$0.26
Q3 25
$-0.14
$0.17
Q2 25
$-0.07
$0.12
Q1 25
$-0.95
$0.06
Q4 24
$-0.53
$0.40
Q3 24
$-1.12
$0.41
Q2 24
$-1.81
$-0.09
Q1 24
$-0.08
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DH
DH
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$180.9M
$97.5M
Total DebtLower is stronger
$156.1M
$22.7M
Stockholders' EquityBook value
$379.0M
$130.3M
Total Assets
$735.5M
$216.3M
Debt / EquityLower = less leverage
0.41×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DH
DH
PBYI
PBYI
Q4 25
$180.9M
$97.5M
Q3 25
$185.9M
$94.4M
Q2 25
$184.2M
$96.0M
Q1 25
$200.7M
$93.2M
Q4 24
$290.2M
$101.0M
Q3 24
$305.4M
$96.7M
Q2 24
$296.5M
$96.8M
Q1 24
$295.2M
$107.2M
Total Debt
DH
DH
PBYI
PBYI
Q4 25
$156.1M
$22.7M
Q3 25
$158.2M
$34.0M
Q2 25
$160.3M
$45.3M
Q1 25
$162.4M
$56.7M
Q4 24
$229.4M
$68.0M
Q3 24
$232.7M
$79.3M
Q2 24
$236.0M
$90.7M
Q1 24
$239.3M
$102.0M
Stockholders' Equity
DH
DH
PBYI
PBYI
Q4 25
$379.0M
$130.3M
Q3 25
$389.7M
$115.3M
Q2 25
$411.2M
$104.7M
Q1 25
$435.9M
$97.1M
Q4 24
$607.2M
$92.1M
Q3 24
$695.6M
$71.1M
Q2 24
$886.3M
$48.5M
Q1 24
$1.2B
$51.0M
Total Assets
DH
DH
PBYI
PBYI
Q4 25
$735.5M
$216.3M
Q3 25
$755.5M
$202.9M
Q2 25
$770.1M
$194.9M
Q1 25
$808.7M
$196.2M
Q4 24
$1.1B
$213.3M
Q3 24
$1.2B
$220.7M
Q2 24
$1.4B
$205.0M
Q1 24
$1.8B
$214.1M
Debt / Equity
DH
DH
PBYI
PBYI
Q4 25
0.41×
0.17×
Q3 25
0.41×
0.30×
Q2 25
0.39×
0.43×
Q1 25
0.37×
0.58×
Q4 24
0.38×
0.74×
Q3 24
0.33×
1.12×
Q2 24
0.27×
1.87×
Q1 24
0.20×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DH
DH
PBYI
PBYI
Operating Cash FlowLast quarter
$2.7M
$14.4M
Free Cash FlowOCF − Capex
$-1.7M
$14.4M
FCF MarginFCF / Revenue
-2.8%
19.1%
Capex IntensityCapex / Revenue
7.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$37.1M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DH
DH
PBYI
PBYI
Q4 25
$2.7M
$14.4M
Q3 25
$15.7M
$9.7M
Q2 25
$9.3M
$14.1M
Q1 25
$26.1M
$3.6M
Q4 24
$8.1M
$15.6M
Q3 24
$19.4M
$11.0M
Q2 24
$14.0M
$1.0M
Q1 24
$16.6M
$11.2M
Free Cash Flow
DH
DH
PBYI
PBYI
Q4 25
$-1.7M
$14.4M
Q3 25
$13.4M
$9.7M
Q2 25
$7.0M
$14.1M
Q1 25
$18.4M
$3.6M
Q4 24
$-2.8M
$15.6M
Q3 24
$18.7M
$11.0M
Q2 24
$13.6M
$1.0M
Q1 24
$16.3M
FCF Margin
DH
DH
PBYI
PBYI
Q4 25
-2.8%
19.1%
Q3 25
22.3%
17.7%
Q2 25
11.5%
26.8%
Q1 25
31.0%
7.7%
Q4 24
-4.4%
26.4%
Q3 24
29.8%
13.7%
Q2 24
21.4%
2.1%
Q1 24
25.7%
Capex Intensity
DH
DH
PBYI
PBYI
Q4 25
7.2%
0.0%
Q3 25
3.8%
0.0%
Q2 25
3.8%
0.0%
Q1 25
13.0%
0.1%
Q4 24
17.5%
0.0%
Q3 24
1.2%
0.0%
Q2 24
0.6%
0.0%
Q1 24
0.4%
0.0%
Cash Conversion
DH
DH
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DH
DH

Subscription Services$58.5M95%
Professional Services$3.0M5%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons